Jim Cramer recommended ImmunityBio as a speculative investment to a caller, indicating potential for the stock.

A health economic analysis has underscored the value of ImmunityBio's (IBRX) ANKTIVA, positioning it favorably against TAR-200. This comparison suggests ANKTIVA's potential benefits in the therapeutic landscape.

ImmunityBio's stock saw a rise as its drug Anktiva underwent FDA review for a label expansion, indicating potential growth for the pharmaceutical company.

An article provides an analysis on whether ImmunityBio, Inc. (IBRX) is a good stock to buy now, focusing on its investment potential.

ImmunityBio Inc. (NASDAQ: IBRX) is reportedly being investigated for potential violations of federal securities laws by Lowey Dannenberg, P.C.

Separate securities fraud class action lawsuits have been filed against ImmunityBio, Inc. and Gemini Space Station, Inc. Both lawsuits set deadlines in May 2026 for lead plaintiff submissions.

Investors in ImmunityBio, Inc. (IBRX) are presented with an opportunity to lead a securities fraud class action lawsuit against the company.

Kaplan Fox is alerting investors to upcoming deadlines to lead securities class action lawsuits against two companies. The deadlines are May 26, 2026, for ImmunityBio, Inc. and May 8, 2026, for Driven Brands Holdings Inc.

ImmunityBio, Inc. (IBRX) announced strong preliminary first-quarter sales, attributing the positive performance to the momentum of its drug ANKTIVA.

ImmunityBio, a biotechnology company, has announced its financial results for the first quarter of the year.

ImmunityBio (IBRX) has been issued a warning by the FDA, though investment firm BTIG has indicated it will maintain a positive stance on the company's prospects.

ImmunityBio Inc. (IBRX) has received a warning letter from the FDA regarding claims made in an advertisement for its cancer therapy.

ImmunityBio (IBRX) has announced that the NCCN Clinical Practice Guidelines have been updated to include ANKTIVA for the treatment of papillary-only non-muscle invasive bladder cancer (NMIBC).

ImmunityBio's stock has seen gains following the inclusion of a new Anktiva indication in the National Comprehensive Cancer Network (NCCN) guidelines.

H.C. Wainwright has increased its price target for ImmunityBio, Inc. (IBRX) to $15 from $10, maintaining a Buy rating on the company's shares.

ImmunityBio is preparing for its fourth-quarter 2026 earnings announcement, with a preview of the upcoming financial report.

ImmunityBio (IBRX) stock has surged significantly after its drug Anktiva propelled a 671% increase in revenue.

ImmunityBio has established an Irish unit and secured a distribution agreement to enhance the availability of its drug Anktiva in Europe.

ImmunityBio's stock surged following the EU's approval of ANKTIVA for bladder cancer treatment.

ImmunityBio (IBRX) has been highlighted as one of the best performing growth stocks in 2026. The biotechnology company has shown significant market gains this year.

Analysts are evaluating ImmunityBio Inc. (IBRX) as a potential momentum stock, assessing its investment appeal.

Jim Cramer recommended waiting for more clarity regarding ImmunityBio before investors consider a serious evaluation of the company's stock.

Investors are being alerted to upcoming deadlines to join securities fraud class action lawsuits filed against ImmunityBio, Inc. and Eos Energy Enterprises. The deadlines for participation are May 26, 2026, for ImmunityBio and May 5, 2026, for Eos Energy.

ImmunityBio (IBRX) has seen its stock jump by 266% this year, a significant increase attributed to the company's global expansion efforts.

Investors in ImmunityBio, Inc. are reminded of the May 26, 2026, filing deadline for a securities fraud class action lawsuit against the company.

ImmunityBio stock slumped on Monday, with the article exploring the reasons behind its decline.

ImmunityBio (IBRX) shares rallied 15% following the firm's announcement that it has raised $100 million to fund its global expansion initiatives.

ImmunityBio has successfully secured $75 million in financing as part of a deal with Oberland Capital.

Palantir's stock fell by 5% as the broader tech sector experienced a sell-off, raising questions about whether the company is being unfairly penalized.

Financial commentator Jim Cramer has expressed skepticism about ImmunityBio, stating that its stock is indicative of a 'magical thinking era' in the market.

ImmunityBio (IBRX) shares fell by 17% due to profit-taking after reaching an intra-day high.

ImmunityBio's stock experienced a significant surge today, with reasons for the increase being explored.

ImmunityBio (IBRX) stock soared to a new high, driven by optimism surrounding the future expansion of its drug Anktiva.

ImmunityBio's stock experiences a significant surge, attracting investor attention.

ImmunityBio Inc. (IBRX) is identified as one of the most shorted mid-cap stocks currently recommended for purchase. The article suggests it's a stock to consider buying now.

Shares of ImmunityBio and Red Cat have experienced significant surges in the stock market today. The reasons behind these sharp increases are being analyzed by investors and market watchers.

ImmunityBio has announced its acquisition of the U.S. rights to the Tokyo strain of Bacillus Calmette-Guérin (BCG), a vaccine primarily used against tuberculosis and also for bladder cancer treatment.

Kessler Topaz Meltzer & Check, LLP has announced the filing of a securities fraud class action lawsuit against ImmunityBio, Inc.

Investors in ImmunityBio, Inc. (IBRX) have been alerted to a May 26, 2026, deadline to participate in a securities fraud class action lawsuit against the company.

Investors of ImmunityBio, Inc. (NASDAQ: IBRX) are advised that a deadline is approaching to contact Kaplan Fox regarding potential securities violations.

Investors in ImmunityBio, Inc. (IBRX) are facing a May 26, 2026, deadline to participate in a securities fraud class action lawsuit against the company.

Investors in ImmunityBio, Inc. (NASDAQ: IBRX) are being encouraged to contact Kaplan Fox before the lead plaintiff deadline on May 26, 2026, indicating a potential legal action or class-action lawsuit.

The deadline for investors to lead a securities class action lawsuit against IMMUNITYBIO has been set for May 26, 2026. Kaplan Fox is inviting affected parties to contact them regarding the legal action.

Investors in ImmunityBio, Inc. (IBRX) are being presented with an opportunity to lead a securities fraud class action lawsuit against the company.

Jim Cramer recommended owning ImmunityBio stock, with the caveat that investors should not own any other speculative stocks alongside it.

ImmunityBio's stock declined after the FDA issued a warning regarding an advertisement and podcast related to its drug Anktiva.

BTIG analysts are projecting an upside for ImmunityBio, Inc. (IBRX), attributing their positive outlook to strong anticipated sales growth for ANKTIVA in 2026.

ImmunityBio (IBRX) announced a significant 700% increase in revenue, primarily attributed to the rapid adoption of its product, ANKTIVA.

ImmunityBio announced its GAAP earnings per share of -$0.06 and reported revenue of $38.2 million for the latest quarter.

ImmunityBio is conducting a clinical trial for a lymphoma drug, following a significant $505 million convertible note change.

ImmunityBio's stock saw an increase after its bladder cancer therapy received approval in the European Union.